Castle Creek Biosciences
Trial Pipeline
Evaluation of D-Fi for the Treatment of Wounds Due to DEB
NCT06892639
A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa
NCT04213261
Safety and Efficacy Study of Isolagen TherapyTM in the Treatment of Nasolabial Fold Wrinkles
NCT00649428
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 3 |
What the Pipeline for Castle Creek Biosciences Shows
According to the ClinicalTrials.gov registry, Castle Creek Biosciences is linked to 3 US clinical trials across every stage of research activity. Of those, 0 studies are currently recruiting — about 0% of the sponsor's indexed portfolio — and 1 are already marked complete, representing roughly 33% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for Castle Creek Biosciences reports 3 late-stage studies (Phase 3 and Phase 4 combined) and 0 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for Castle Creek Biosciences is Bilateral Nasolabial Fold Wrinkles with 1 linked trial, and 2 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.